A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ

MEDA Pharma GmbH & Co. KG72 enrolled

Overview

The purpose of the study is to obtain recurrence rates and long-term safety data for patients who had been treating actinic keratoses on the face and scalp with 5 % Imiquimod Cream in a previous study.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Actinic Keratoses

Interventions

ImiquimodDRUG

No defined treatments were given during this study.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 100% clearance of Actinic Keratosis (AK) lesions in the 1487 IMIQ study Exclusion Criteria: * used any treatments in the previous treatment area within 24 hours prior to the follow-up visit

Outcomes

Primary Outcomes

Efficacy

Efficacy was evaluated by counting AK lesions in the previous treatment area. Subjects at the 1-year follow-up visit with recurrence of lesion(s).

Time frame: one year after completion of study 1487-Imiq

Safety

Safety was evaluated by assessing the area of previous treatment for LSRs and skin quality

Time frame: one year after completion of study 1487-Imiq

Adverse Events

AEs considered by investigator to be possibly or probably related to the 1487-Imiq study medication were documented and recorded.

Time frame: one year after completion of study 1487-Imiq

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.